NO802139L - OUTPUT CONNECTIONS FOR PREPARING MORPHINE DERIVATIVES, AND PROCEDURE FOR PREPARING OUTPUT - Google Patents
OUTPUT CONNECTIONS FOR PREPARING MORPHINE DERIVATIVES, AND PROCEDURE FOR PREPARING OUTPUTInfo
- Publication number
- NO802139L NO802139L NO802139A NO802139A NO802139L NO 802139 L NO802139 L NO 802139L NO 802139 A NO802139 A NO 802139A NO 802139 A NO802139 A NO 802139A NO 802139 L NO802139 L NO 802139L
- Authority
- NO
- Norway
- Prior art keywords
- approx
- boron
- compounds
- amide
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title description 5
- 150000001408 amides Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 23
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 19
- 229960000805 nalbuphine Drugs 0.000 claims description 19
- 239000012649 demethylating agent Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 claims description 8
- -1 amide compounds Chemical class 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 230000017858 demethylation Effects 0.000 claims description 6
- 238000010520 demethylation reaction Methods 0.000 claims description 6
- 239000012429 reaction media Substances 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 150000001639 boron compounds Chemical class 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 230000001335 demethylating effect Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013067 intermediate product Substances 0.000 description 6
- 229960002085 oxycodone Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229960005118 oxymorphone Drugs 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- RIKMCJUNPCRFMW-ISWURRPUSA-N Noroxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 RIKMCJUNPCRFMW-ISWURRPUSA-N 0.000 description 4
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 2
- ZIQIQOUPRHPOIT-UHFFFAOYSA-N cyclobutylazanide Chemical compound [NH-]C1CCC1 ZIQIQOUPRHPOIT-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- FLOZEJLRMHLESX-UHFFFAOYSA-N cyclobutadienecarboxylic acid Chemical compound OC(=O)C1=CC=C1 FLOZEJLRMHLESX-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Description
Foreliggende oppfinnelse vedrører nye mellomprodukter egnet for bruk ved fremstilling av morfinderivater, The present invention relates to new intermediate products suitable for use in the production of morphine derivatives,
samt fremgangsmåte til fremstilling av mellomproduktene. as well as the method for producing the intermediate products.
Foreliggende forbindelser er mellomprodukter somThe compounds present are intermediates such as
kan reduseres for dannelse av morfinderivater som ikke innehar de uønskede bivirkninger ved morfin, f.eks. ned-settelse av åndedrett og lignende. Disse mellomprodukter er av den typen som er beskrevet i US-patent nr. 3.393.197, og slike forbindelser har følgende generelle formel: can be reduced to form morphine derivatives that do not have the unwanted side effects of morphine, e.g. reduction of breathing and the like. These intermediates are of the type described in US Patent No. 3,393,197, and such compounds have the following general formula:
hvor R er en alifatisk gruppe. En spesielt nyttig forbindelse fra den ovenfor angitte.gruppe er kjent som nalbufin (hvor R i formelen er cyklobutyl). where R is an aliphatic group. A particularly useful compound from the above group is known as nalbuphine (where R in the formula is cyclobutyl).
En benyt.tet syntese for nalbufin og nalbufinlig-nende forbindelser fra oksykodon, et lett tilgjengelig ut-gangsmateriale, kan representeres som føiger: A useful synthesis for nalbuphine and nalbuphine-like compounds from oxycodone, an easily available starting material, can be represented as follows:
Ifølge prosessene blir oksykodon demytelert for dannelse av oksymorfon, f.eks. som beskrevet i US-søknad nr. 953056 (internasjonal søknad nr. PCT/US 79/00862. Oksykodon-oksymorfon-omdannelsen, det første trinn i det ovenfor angitte reaksjonsskjema tar fra ca. 3 til 18 timer ved romtemperatur i nærvær av et bor-demetyleringsmiddel, eller ca. 1 time ved omkring 190°C i nærvær av pyridin-hydroklorid. Oksymorfon omdannes deretter til noroksymorfon som igjen acetyleres for dannelse av et cyklobutylamid-mellomprodukt (esteramid III). Acetylering oppnås' ved reaksjon mellom cyklobutankarboksylsyre og etylklorformiat for dannelse av et blandet anhydrid som deretter reagerer med noroksymorfon for dannelse av esteramidet som kan reduseres med litiumaluminiumhydrid til dannelse av produktet nalbufin eller en forbindelse av nalbufintypen. According to the processes, oxycodone is demethylated to form oxymorphone, e.g. as described in US Application No. 953056 (International Application No. PCT/US 79/00862. The oxycodone-oxymorphone conversion, the first step in the above reaction scheme takes from about 3 to 18 hours at room temperature in the presence of a boron -demethylating agent, or about 1 hour at about 190°C in the presence of pyridine hydrochloride. Oxymorphone is then converted to noroxymorphone which is again acetylated to form a cyclobutylamide intermediate (esteramide III). Acetylation is achieved by reaction between cyclobutanecarboxylic acid and ethyl chloroformate for forming a mixed anhydride which then reacts with noroxymorphone to form the ester amide which can be reduced with lithium aluminum hydride to form the product nalbuphine or a nalbuphine-type compound.
Selv om denne prosess er av verdi, er den forbun-det med visse problemer. Oksykodon-oksymorfon-omdannelsen kan være temmelig tidkrevende og dette er uønsket i en kommersiell prosess ^ Dannelsen av cyklobutylamid-mellom-produktet under anvendelse av reaksjonen mellom cyklobuta-dienkarboksylsyre og etylklorformiat for dannelse av et blandet anhydrid som deretter reagerer med noroksymorfon til dannelse av amidet, er en temmelig langsom reaksjon. Det ville følgelig være meget ønskelig f.eks. å benytte cyklobutyrylklorid for direkte dannelse av amidet isteden for det blandede anhydrid, slik at man får hurtigere reaksjonstider. Videre, på grunn av de komplekse forhold og sidereaksjoner ved arbeid med et noroksymorfon-mellomprodukt, gir en forandring i rekkefølgen av reaksjonstrinn potensielle fordeler i både utbytter og omsetningsmengder. Although this process is of value, it is associated with certain problems. The oxycodone-oxymorphone conversion can be quite time consuming and this is undesirable in a commercial process ^ The formation of the cyclobutylamide intermediate using the reaction between cyclobutadienecarboxylic acid and ethyl chloroformate to form a mixed anhydride which then reacts with noroxymorphone to form the amide , is a rather slow reaction. It would therefore be highly desirable e.g. to use cyclobutyryl chloride for direct formation of the amide instead of the mixed anhydride, so that faster reaction times are obtained. Furthermore, due to the complex conditions and side reactions when working with a noroxymorphone intermediate, a change in the sequence of reaction steps offers potential advantages in both yields and turnover.
Foreliggende oppfinnelse angår et N-acy1-dihydro-14-hydroksynormorfon-mellomprodukt (i det følgende beteg-net mellomprodukt-amid II) som er nyttig ved fremstilling av nalbufin og produkter av nalbufintypen. Mellomprodukt-amid II har følgende generelle formel. The present invention relates to an N-acyl-dihydro-14-hydroxynormorphone intermediate (hereinafter referred to as intermediate amide II) which is useful in the production of nalbuphine and products of the nalbuphine type. Intermediate amide II has the following general formula.
hvor R er en hydrokarbylgruppe med opp til ca. 6 karbonatomer. where R is a hydrocarbyl group with up to approx. 6 carbon atoms.
I foretrukne utførelser av oppfinnelsen er gruppen R i mellomprodukt-amid II mettet og kan ha opp til ca. 6 karbonatomer, fortrinnsvis ca. 3-6 karbonatomer. R kan således være alkyl med opp til ca. 6 karbonatomer, fortrinnsvis cykloalkyl med fra 3 til ca. 6 karbonatomer, f.eks. cyklopropyl, cyklobutyl og cyklopentyl, spesielt cyklobu-ty 1. In preferred embodiments of the invention, the group R in intermediate amide II is saturated and can have up to approx. 6 carbon atoms, preferably approx. 3-6 carbon atoms. R can thus be alkyl with up to approx. 6 carbon atoms, preferably cycloalkyl with from 3 to approx. 6 carbon atoms, e.g. cyclopropyl, cyclobutyl and cyclopentyl, especially cyclobuty 1.
For fremstilling av nalbufin og forbindelser av nalbufintypen fra oksykodon er det også utviklet en ny syntetisk vei som kan representeres ved følgende reaksjons-skjerna: For the production of nalbuphine and compounds of the nalbuphine type from oxycodone, a new synthetic pathway has also been developed which can be represented by the following reaction core:
Denne reaksjonsvei inkluderer fremstilling av de nye mellomprodukt-amid II forbindelser. Ifølge denne nye syntese blir oksykodon først omdannet i nærvær av CNBr og svovelsyre til noroksykodon som deretter acyleres under dannelse av et første mellomprodukt-amid (mellomprodukt-amid I i ovenstående reaksjonsskjema). Det første mellomprodukt-amid/som ikke behøver å isoleres, blir. deretter demetylert for dannelse av et annet mellomprodukt-amid (mellomprodukt-amid II i reaksjonsskjemaet) som kan isoleres og reduseres for dannelse av nalbufin eller forbindelser av nalbufintypen.Demetyleringen av mellomprodukt-amid I forbindelser til mellomprodukt-amid II forbindelser representerer et hovedavvik fra tidligere syn-teseveier for fremstilling av nalbufin og forbindelser av nalbufintypen, og mellomprodukt-amid II forbindelsene er nye forbindelser. Ved å benytte denne nye syntesevei omfatter de nye mellomprodukt-amider ifølge foreliggende oppfinnelse,. kan nalbufin og forbindelser av nalbufintypen. fremstilles i forbedrede utbytter under mildere'reaksjons-betingelser og med kortere reaksjonstider sammenlignet med kjente syntesemetoder som angitt i det ovenfor først angitte reaksjonsskjema. This reaction pathway includes the preparation of the new intermediate amide II compounds. According to this new synthesis, oxycodone is first converted in the presence of CNBr and sulfuric acid to noroxycodone which is then acylated to form a first intermediate amide (intermediate amide I in the above reaction scheme). The first intermediate amide/which does not need to be isolated becomes then demethylated to form another intermediate amide (intermediate amide II in the reaction scheme) which can be isolated and reduced to form nalbuphine or compounds of the nalbuphine type. The demethylation of intermediate amide I compounds to intermediate amide II compounds represents a major departure from previous synthesis routes for the production of nalbuphine and compounds of the nalbuphine type, and the intermediate amide II compounds are new compounds. By using this new synthesis route, the new intermediate product amides according to the present invention comprise. can nalbuphine and compounds of the nalbuphine type. are produced in improved yields under milder reaction conditions and with shorter reaction times compared to known synthesis methods as indicated in the first reaction scheme indicated above.
Ifølge, denne nye demetyleringsprosess blir metyl-gruppen fjernet fra metoksysubstituenten i en første mellomprodukt-amid forbindelse (mellomprodukt-amid I) som har følgende formel: According to this new demethylation process, the methyl group is removed from the methoxy substituent in a first intermediate amide compound (intermediate amide I) which has the following formula:
hvor R har den be.tydning som angitt i forbindelse med formelen for mellomprodukt-amid II, ved omsetning av mellomprodukt-amid I med et demetyleringsmiddel under egnede be-tingelser hvorved mellomprodukt-amid II fremstilles. Reaksjonen utføres under demetyleringsbetingelser som kan være milde, og reaksjonen kan f.eks. foretas ved temperaturer fra ca. 0 til 4 0°C. where R has the meaning given in connection with the formula for intermediate product amide II, by reacting intermediate product amide I with a demethylating agent under suitable conditions whereby intermediate product amide II is produced. The reaction is carried out under demethylation conditions which can be mild, and the reaction can e.g. carried out at temperatures from approx. 0 to 40°C.
Isolering av mellomprodukt-amid II er enkel og likefrem, og kan oppnås ved enkel utfelling uten at det er nødvendig med noen videre ekstraksjon for å fjerne utgangs-materialet (etere). Denne enkle separering står i merkbar kontrast til separeringen av andre fenolholdige forbindelser av denne generelle type fra deres tilsvarende etere. Det totale utbytte av morfintype-produktet fra oksykodon-utgangsmaterialet kan være så meget som ca. 40% eller mer hvilket er en forbedring i forhold til oksykodon-oksymorfon prosessen som beskrevet ovenfor og illustrert i det først angitte reaksjohsskjerna. Isolation of intermediate amide II is simple and straightforward, and can be achieved by simple precipitation without the need for any further extraction to remove the starting material (ethers). This easy separation is in marked contrast to the separation of other phenolic compounds of this general type from their corresponding ethers. The total yield of the morphine-type product from the oxycodone starting material can be as much as approx. 40% or more which is an improvement over the oxycodone-oxymorphone process as described above and illustrated in the first indicated reaction core.
Ved fremstilling av mellomprodukt-amid II forbindelsene anvendes en demetylerende mengde av et passende middel, f.eks. en borforbindelse. Midlet kan demetylere metoksygruppen, men kan ikke danne flere uønskede bipro-dukter. Borforbindelsene omfatter borhalogenidene slik som bortribromid, bortriklorid og reaksjonsproduktet av slike halogenider med alkoholer, dvs. de som inneholder 1-10 karbonatomer, fortrinnsvis lavere alkoholer inneholdende 1-6 karbonatomer, f.eks. metanol, propanol, butanol, heksanol osv. Det foretrukne dernetyleringsmiddel er bortribromid som er noe mer aktivt sammenlignet med demetyleringsmidlet bortriklorid. Demetyleringsmidlet kan være tilstede i en mengde på fra ca. 2,5 til 8 mol, fortrinnsvis ca. 3,5 til 6,5 mol, f.eks. ca. 6 mol, av demetyleringsmidlet pr. mol mellomprodukt-amid I. Det oppnås ingen særlig fordel ved anvendelse av noe mer enn omkring 8 mol. Anvendelse av mindre enn ca. 2,5 mol kan resultere i ufullstendig reaksjon. When preparing the intermediate amide II compounds, a demethylating amount of a suitable agent is used, e.g. a boron compound. The agent can demethylate the methoxy group, but cannot form more unwanted by-products. The boron compounds include the boron halides such as boron tribromide, boron trichloride and the reaction product of such halides with alcohols, i.e. those containing 1-10 carbon atoms, preferably lower alcohols containing 1-6 carbon atoms, e.g. methanol, propanol, butanol, hexanol, etc. The preferred demethylating agent is boron tribromide which is somewhat more active compared to the demethylating agent boron trichloride. The demethylating agent can be present in an amount of from approx. 2.5 to 8 mol, preferably approx. 3.5 to 6.5 moles, e.g. about. 6 mol, of the demethylating agent per mol of intermediate amide I. No particular advantage is obtained by using anything more than about 8 mol. Application of less than approx. 2.5 mol may result in incomplete reaction.
Demetyleringsbetingelsene omfatter passende reaksjonstider, f.eks. fra ca. 0,5 til 4 timer i satsvise metoder, og reaks.jonstemperaturer, f.eks. fra ca. 0 til 40°C, . fortrinnsvis fra ca. 15 til 25°C. I denne forbindelse skal det nevnes at temperaturen for reaksjonsmediet til hvilket demetyleringsmidlet kan tilsettes, kan være fra ca. -25 til +20°C, fortrinnsvis fra ca. +10 til +20°C. Etter at mellomprodukt-amid I og demetyleringsmidlet er kombinert, kan reaksjonsvårmen resultere i en økning i temperaturen på reaksjonsmediet, skjønt temperaturen kan reguleres for å unngå upassende temperaturøkninger. Høye temperaturer i reaksjonsmediet kan resultere i lavere utbytter av mellomprodukt-amid II. I denne forbindelse kan det være for-delaktig at det i reaksjonsmediet anvendes et vesentlig inert oppløsningsmiddel som ikke vil reagere med demetyleringsmidlet, f.eks. klorloenzen. Demetyleringsmidlet kan inkorporeres i oppløsningsmidlet og oppløsningen kombine-res med mellomprodukt-amid I reaktanten. Alternativt kan demetyleringsmidlet og oppløsningsmidlet tilsettes til reaksjonsmediet separat. Mellomprodukt-amid I kan f.eks. ganske enkelt blandes med demetyleringsmidlet; •Utvinning av mellomprodukt-amid II kan oppnåes ved enkel utfelling uten at. det er nødvendig med ytterligere ekstraksjon for å fjerne utgangsmaterialer. Dette er en betydelig fordel ved foreliggende oppfinnelse sammenlignet med andre prosesser for fremstilling av nalbufin og forbindelser av nalbufintypen. Totalt kan utbytter av nalbufin og forbindelser av nalbufintypen fra oksykodon ved foreliggende fremgangsmåte være omkring 4 0% eller mer i forhold til 34% eller mindre for de tidligere kjente prosesser. The demethylation conditions include suitable reaction times, e.g. from approx. 0.5 to 4 hours in batch methods, and reaction temperatures, e.g. from approx. 0 to 40°C, . preferably from approx. 15 to 25°C. In this connection, it should be mentioned that the temperature of the reaction medium to which the demethylating agent can be added can be from approx. -25 to +20°C, preferably from approx. +10 to +20°C. After the intermediate amide I and the demethylating agent are combined, the heat of reaction may result in an increase in the temperature of the reaction medium, although the temperature may be controlled to avoid inappropriate temperature increases. High temperatures in the reaction medium can result in lower yields of intermediate amide II. In this connection, it can be advantageous to use a substantially inert solvent in the reaction medium which will not react with the demethylating agent, e.g. the chlorloene. The demethylating agent can be incorporated into the solvent and the solution combined with the intermediate amide I reactant. Alternatively, the demethylating agent and the solvent can be added to the reaction medium separately. Intermediate amide I can e.g. simply mixed with the demethylating agent; •Recovery of intermediate amide II can be achieved by simple precipitation without at. additional extraction is required to remove starting materials. This is a significant advantage of the present invention compared to other processes for the production of nalbuphine and compounds of the nalbuphine type. In total, yields of nalbuphine and compounds of the nalbuphine type from oxycodone by the present method can be about 40% or more in relation to 34% or less for the previously known processes.
Følgende eksempler Illustrerer oppfinnelsen, og alle delangivelser er beregnet på vekt med mindre annet er angitt. The following examples illustrate the invention, and all part statements are calculated by weight unless otherwise stated.
Eksempel IExample I
Fremstilling av mellomprodukt- amid IPreparation of intermediate amide I
Til en 500 ml kolbe tilsettes 200 ml vannfri tetra-hydrofuran (THF) og 6,5 g etylklorformiat. Blandingen av-kjøles til 5°C. Til denne kolbe tilsettes langsomt en blanding inneholdende 6 g cyklobutankarboksylsyre, 8,5 ml trietylamin og 50 ml THF. Temperaturen bør ikke stig.e over 10°C under denne tilsetning. Under omrøring får blandingens temperatur anledning til å stige til 20-25°C i løpet av et tidsrom på 1-2 timer. Trietylaminsaltet frafiltreres og 14 g noroksykodon og 1,5 ml trietylamin tilsettes til opp-løsningen. Blandingen omrøres i 1-2 timer ved romtemperatur. THF-materialet fordampes og det resulterende produkt for-tynnes med 200 ml klorbenzen. 200 ml of anhydrous tetrahydrofuran (THF) and 6.5 g of ethyl chloroformate are added to a 500 ml flask. The mixture is cooled to 5°C. A mixture containing 6 g of cyclobutanecarboxylic acid, 8.5 ml of triethylamine and 50 ml of THF is slowly added to this flask. The temperature should not rise above 10°C during this addition. During stirring, the temperature of the mixture is allowed to rise to 20-25°C over a period of 1-2 hours. The triethylamine salt is filtered off and 14 g of noroxycodone and 1.5 ml of triethylamine are added to the solution. The mixture is stirred for 1-2 hours at room temperature. The THF material is evaporated and the resulting product is diluted with 200 ml of chlorobenzene.
Eksempel IIExample II
Spalting av mellomprodukt- amid I med bortribromidCleavage of intermediate amide I with boron tribromide
100 ml mellomprodukt-amid I oppløsning som frem-stilt i eksempel I, tilsettes til en 500 ml kolbe og av-kjøles til 10-15°C. En blanding inneholdende 100 ml klorbenzen og 6-11 ml BBr^ tilsettes langsomt til kolben slik at temperaturen i blandingen ikke stiger over 20°C Molforholdet mellom BBr^og mellomprodukt-amid I i kolben 100 ml of intermediate amide I solution as prepared in Example I is added to a 500 ml flask and cooled to 10-15°C. A mixture containing 100 ml of chlorobenzene and 6-11 ml of BBr^ is slowly added to the flask so that the temperature in the mixture does not rise above 20°C The molar ratio between BBr^ and intermediate amide I in the flask
kan variere fra ca. 2,8 til 5,1:1. Blandingen omrøres ved 20-25°C i 30 min. og bråkjøles ved tilsetning av blandingen til 300 ml isvann. Det faste stoffet .frafiltreres, vaskes med klorbenzen og lufttørkes. Det faste, stoffet oppslemmes deretter i metanol, filtreres, vaskes igjen med metanol og tørkes. Det utvunnede faste stoff veier 4,4-4,9 g, hvilket representerer utbytter på 51-57% basert på noroksykodon. can vary from approx. 2.8 to 5.1:1. The mixture is stirred at 20-25°C for 30 min. and quench by adding the mixture to 300 ml of ice water. The solid substance is filtered off, washed with chlorobenzene and air-dried. The solid is then slurried in methanol, filtered, washed again with methanol and dried. The recovered solid weighs 4.4-4.9 g, representing yields of 51-57% based on noroxycodone.
Eksempel IIIExample III
Spalting av mellomprodukt- amid I med bortrikloridCleavage of intermediate amide I with boron trichloride
100 ml mellomprodukt-amid I oppløsning som frem-stilt i eksempel I, tilsettes til en 500 ml kolbe og av-kjøles til 10-15°. Mens denne oppløsning avkjøles,fremstilles en oppløsning av bortriklorid ved innføring av bortrikloridgass i 100 ml klorbenzen. Den således dannede bortrikloridoppløsning tilsettes til den avkjølte oppløs-ning fra eksempel I mens temperaturen holdes under 20°C. Molforholdet mellom BCl^og -mellomprodukt-amid A i kolben er ca. 7,7:1. Reaksjonsblandingen omrøres i 4 timer ved 20-25°C og bråkjøles i 300 ml isvann. Det faste stoffet frafiltreres, vaskes med klorbenzen og lufttørkes. Det faste stoff oppslemmes deretter i metanol, filtreres, vaskes på nytt med metanol og tørkes. Det oppnådde faste stoff veier 3,6-4,0 g, hvilket representerer et utbytte på 42-47% basert på noroksykodon. 100 ml of intermediate amide I solution as prepared in example I is added to a 500 ml flask and cooled to 10-15°. While this solution is cooling, a solution of boron trichloride is prepared by introducing boron trichloride gas into 100 ml of chlorobenzene. The boron trichloride solution thus formed is added to the cooled solution from example I while the temperature is kept below 20°C. The molar ratio between BCl^ and -intermediate amide A in the flask is approx. 7.7:1. The reaction mixture is stirred for 4 hours at 20-25°C and quenched in 300 ml of ice water. The solid is filtered off, washed with chlorobenzene and air-dried. The solid is then slurried in methanol, filtered, washed again with methanol and dried. The solid obtained weighs 3.6-4.0 g, which represents a yield of 42-47% based on noroxycodone.
Eksempler IV - XIXExamples IV - XIX
Variasjon av temperatur, konsentrasjon og reaksjonstid Variation of temperature, concentration and reaction time
Tabell 1 illustrerer ytterligere forsøk som ble utført under anvendelse av metoder i likhet med de som er angitt i eksemplene II og III, skjønt det var varia-sjoner i tilsetningstemperatur for BBr^ og BCl^, reak-sjons temperatur etter tilsetning, reaksjonstid og pro-duktutbytte, alt angitt i tabell 1. Noen av resultatene, spesielt i de første forsøk, er ikke i overensstemmelse med de resultater som senere ble oppnådd. Grunnen for Table 1 illustrates further experiments which were carried out using methods similar to those set out in Examples II and III, although there were variations in addition temperature for BBr 2 and BCl 2 , reaction temperature after addition, reaction time and pro - duct yield, all indicated in table 1. Some of the results, especially in the first attempts, are not in accordance with the results that were later obtained. The reason for
.disse forskjeller er ikke helt ut forstått, skjønt de kan tillegges, i det minste delvis, en mangel på erfaring ved utførelse av reaksjonen i begynnelsen og det faktum at et materiale som ble isolert til å begynne med faktisk ikke .these differences are not fully understood, although they may be attributed, at least in part, to a lack of experience in performing the reaction at the outset and the fact that a material initially isolated does not actually
var produktmateriale. I de senere forsøk ble, som illustrert, gode utbytter av produktet oppnådd.. was product material. In the later experiments, as illustrated, good yields of the product were obtained.
Claims (10)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6527579A | 1979-08-09 | 1979-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO802139L true NO802139L (en) | 1981-02-10 |
Family
ID=22061564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO802139A NO802139L (en) | 1979-08-09 | 1980-07-16 | OUTPUT CONNECTIONS FOR PREPARING MORPHINE DERIVATIVES, AND PROCEDURE FOR PREPARING OUTPUT |
Country Status (16)
Country | Link |
---|---|
JP (1) | JPS56501010A (en) |
AU (1) | AU6116580A (en) |
BE (1) | BE884671A (en) |
DD (1) | DD154541A5 (en) |
DK (1) | DK151781A (en) |
ES (1) | ES494122A0 (en) |
FI (1) | FI802479A (en) |
FR (1) | FR2465735A1 (en) |
GB (1) | GB2066256A (en) |
IL (1) | IL60783A0 (en) |
IT (1) | IT8068267A0 (en) |
NL (1) | NL8020319A (en) |
NO (1) | NO802139L (en) |
PL (1) | PL226162A1 (en) |
SE (1) | SE8102214L (en) |
WO (1) | WO1981000409A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795813A (en) * | 1981-08-17 | 1989-01-03 | The Florida Board Of Regents On Behalf Of The Florida State University | Synthesis of derivatives of codeine and other 3-O-alkylmorphines |
US5668285A (en) * | 1986-10-31 | 1997-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates |
DK0496830T3 (en) * | 1989-10-16 | 1999-10-11 | Us Health | Total synthesis of northebain, normorphine, noroxymorphone enantiomers and derivatives via N-nor intermediates |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA913077A (en) * | 1972-10-24 | J. Pachter Irwin | Process of preparing n-substituted 14-hydroxydihydronormorphines | |
US3249616A (en) * | 1966-05-03 | Ix-dfflydroxy-g-oxo-n-phenethylmor- phinan (cis) and production thereof | ||
US2772270A (en) * | 1954-10-21 | 1956-11-27 | M J Lewenstein | 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone |
US2806033A (en) * | 1955-08-03 | 1957-09-10 | Lewenstein | Morphine derivative |
BE638369A (en) * | 1962-10-10 | |||
US3332950A (en) * | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
NL7106612A (en) * | 1971-05-13 | 1972-11-15 | N-cycloalkylalkyl-14-hydroxy-dihydronormorphines - - by o-demethylation of 14-methoxy cpds | |
US3775414A (en) * | 1972-05-10 | 1973-11-27 | Bristol Myers Co | Process for the preparation of 14-hydroxymorphinan derivatives |
US4161597A (en) * | 1976-12-20 | 1979-07-17 | Research Corporation | N-alkyl-14-hydroxymorphinans and derivatives |
-
1980
- 1980-07-16 NO NO802139A patent/NO802139L/en unknown
- 1980-08-07 AU AU61165/80A patent/AU6116580A/en not_active Abandoned
- 1980-08-07 NL NL8020319A patent/NL8020319A/en not_active Application Discontinuation
- 1980-08-07 IL IL60783A patent/IL60783A0/en unknown
- 1980-08-07 JP JP50198480A patent/JPS56501010A/ja active Pending
- 1980-08-07 WO PCT/US1980/000998 patent/WO1981000409A1/en active Application Filing
- 1980-08-07 GB GB8107295A patent/GB2066256A/en not_active Withdrawn
- 1980-08-07 FI FI802479A patent/FI802479A/en not_active Application Discontinuation
- 1980-08-07 BE BE0/201677A patent/BE884671A/en unknown
- 1980-08-07 IT IT8068267A patent/IT8068267A0/en unknown
- 1980-08-08 FR FR8017530A patent/FR2465735A1/en not_active Withdrawn
- 1980-08-08 ES ES494122A patent/ES494122A0/en active Granted
- 1980-08-09 PL PL22616280A patent/PL226162A1/xx unknown
- 1980-09-08 DD DD80223221A patent/DD154541A5/en unknown
-
1981
- 1981-04-03 DK DK151781A patent/DK151781A/en not_active Application Discontinuation
- 1981-04-07 SE SE8102214A patent/SE8102214L/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK151781A (en) | 1981-04-03 |
IL60783A0 (en) | 1980-10-26 |
SE8102214L (en) | 1981-04-07 |
JPS56501010A (en) | 1981-07-23 |
FR2465735A1 (en) | 1981-03-27 |
PL226162A1 (en) | 1981-04-24 |
BE884671A (en) | 1980-12-01 |
IT8068267A0 (en) | 1980-08-07 |
GB2066256A (en) | 1981-07-08 |
AU6116580A (en) | 1981-02-12 |
NL8020319A (en) | 1981-07-01 |
ES8104296A1 (en) | 1981-04-16 |
DD154541A5 (en) | 1982-03-31 |
WO1981000409A1 (en) | 1981-02-19 |
FI802479A (en) | 1981-02-10 |
ES494122A0 (en) | 1981-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4187249A (en) | Promoting the reaction of sodium salts of formyl derivatives of aromatic amines to form nitrodiarylamines | |
US4140716A (en) | Process for making an amide of formic acid and forming nitrodiarylamine therefrom | |
US4144397A (en) | Preparation of 2-aryl-propionic acids by direct coupling utilizing a mixed magnesium halide complex | |
US4647689A (en) | Preparation of alkyl trifluoroacetoacetate | |
NO802139L (en) | OUTPUT CONNECTIONS FOR PREPARING MORPHINE DERIVATIVES, AND PROCEDURE FOR PREPARING OUTPUT | |
EP0858993B1 (en) | Method of producing keto acids | |
US5200551A (en) | Method of preparing an intermediate for the manufacture of bambuterol | |
US4486599A (en) | Process for preparing the 2',4'-difluoro-4-hydroxy-(1,1'-diphenyl)-3-carboxylic acid | |
US3998880A (en) | Production of N,N-diethyl 2(α-naphthoxy)propionamide | |
JP3962531B2 (en) | Method for producing 1,3-di (2-p-hydroxyphenyl-2-propyl) benzene | |
JPS6026395B2 (en) | Synthesis method of N-trialkylsilylmethylurea | |
US4052402A (en) | Process for synthesizing codeinone from thebaine | |
US4751314A (en) | Preparation of tetrachloro-3-iminoisoindolin-1-one | |
WO1998055445A1 (en) | A process for the preparation of 1-bromoethyl acetate | |
US2591313A (en) | Process for producing alpha | |
KR0169558B1 (en) | Process for preparation of 2-amino-3,5-dibromobenzaldehyde | |
JP2894366B2 (en) | Method for producing deacetylcolchicine | |
JPH04182440A (en) | Production of 3,5-difluoro-1-bromobenzene | |
CN117720464A (en) | Preparation method of 2-chloro-5, 6-dihydro-cyclopentyl [ B ] pyridine-7-ketone | |
CN116082181A (en) | Method for preparing 3-amino-5-ethoxy-benzoic acid | |
JPS6337104B2 (en) | ||
CN114656401A (en) | Method for preparing 4-chloropyridine-2-methyl formate serving as sorafenib key intermediate and suitable for industrial production | |
KR830002203B1 (en) | Method for preparing isopropyl 4, 10-dihydro-10-oxothieno [3, 2-c] [1] benzoxepin-8-acetate | |
US5571916A (en) | Process to prepare diazinon | |
US2778835A (en) | Synthesis of 1-benzamido-1-phenyl-3-piperidinopropane |